Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 PATENT ANALYSIS
4.3.1 PATIENT FLOW DIAGRAM
4.3.2 KEY PRICING STRATEGIES
4.3.3 FUTURE THERAPIES
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES
4.4 EUROPE CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET
4.5 SUPPLY CHAIN ECOSYSTEM
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: EUROPE PEMPHIGUS VULGARIS MARKET
4.7 EPIDEMIOLOGY: EUROPE PEMPHIGUS VULGARIS MARKET
4.7.1 INCIDENCE BY GENDER
4.7.2 TREATMENT RATE
4.7.3 MORTALITY RATE
4.7.4 PATIENT TREATMENT SUCCESS RATES
5 EUROPE PEMPHIGUS VULGARIS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE
6.3.2 INCREASING HEALTHCARE FACILITIES
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT
6.4 CHALLENGES
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES
7 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT
7.1 OVERVIEW
7.2 TREATMENT
7.3 DIAGNOSIS
8 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE
8.1 OVERVIEW
8.2 ADULTS
8.3 GERIATRIC
8.4 PEDIATRIC
9 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 RESEARCH INSTITUTES
9.5 OTHERS
10 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITALS PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K.
11.1.3 FRANCE
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 SWITZERLAND
11.1.7 TURKEY
11.1.8 RUSSIA
11.1.9 BELGIUM
11.1.10 NETHERLANDS
11.1.11 DENMARK
11.1.12 NORWAY
11.1.13 FINLAND
11.1.14 POLAND
11.1.15 SWEDEN
11.1.16 REST OF EUROPE
12 EUROPE PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 SANOFI
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 REGENERON PHARMACEUTICALS INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 JOHNSON & JOHNSON SERVICES, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 ASTRAZENECA
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ACCORD HEALTHCARE
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 AMGEN INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ARTIVA BIOTHERAPEUTICS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PIPELINE PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 BAXTER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 BIOXPRESS THERAPEUTICS SA
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 CABALETTA BIO INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.14 CIPLA HEALTH LTD
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 CELLTRION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 CSL
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 F. HOFFMANN- LA ROCHE LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT/NEWS
14.19 FRESENIUS KABI AG
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENT
14.2 GSK PLC
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENT
14.21 GRIFOLS, S.A.
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 INCYTE
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 NOVARTIS AG
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENT
14.24 LILLY
14.24.1 COMPANY SNAPSHOT
14.24.2 REVENUE ANALYSIS
14.24.3 PRODUCT PORTFOLIO
14.24.4 RECENT DEVELOPMENT
14.25 OCTAPHARMA AG
14.25.1 COMPANY SNAPSHOT
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT/NEWS
14.26 PFIZER INC.
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT
14.27 RAKSHIT DRUGS PVT. LTD
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENT
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD.
14.28.1 COMPANY SNAPSHOT
14.28.2 REVENUE ANALYSIS
14.28.3 PRODUCT PORTFOLIO
14.28.4 RECENT DEVELOPMENT
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.29.1 COMPANY SNAPSHOT
14.29.2 REVENUE ANALYSIS
14.29.3 PRODUCT PORTFOLIO
14.29.4 RECENT DEVELOPMENT
14.3 ZYDUS GROUP
14.30.1 COMPANY SNAPSHOT
14.30.2 REVENUE ANALYSIS
14.30.3 PRODUCT PORTFOLIO
14.30.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 EUROPE PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE EUROPE PEMPHIGUS VULGARIS MARKET
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE EUROPE PEMPHIGUS VULGARIS MARKET
TABLE 4 SURVIVAL RATES IN PEMPHIGUS VULGARIS
TABLE 5 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2028-2032 (USD MILLION)
TABLE 7 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 8 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 10 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 11 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 14 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 15 EUROPE ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 16 EUROPE GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 17 EUROPE PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 18 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 19 EUROPE HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 20 EUROPE SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 21 EUROPE RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 22 EUROPE OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 23 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 24 EUROPE HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 25 EUROPE RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 26 EUROPE ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 27 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 29 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 30 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 31 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 32 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 33 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 34 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 35 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 36 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 37 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 38 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 39 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 40 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 41 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 42 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 43 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 44 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 45 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 46 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 47 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 48 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 49 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 50 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 51 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 52 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 53 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 54 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 55 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 56 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 57 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 59 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 60 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 61 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 62 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 63 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 64 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 65 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 66 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 67 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 69 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 70 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 71 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 72 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 74 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 75 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 76 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 77 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 79 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 80 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 81 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 82 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 83 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 84 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 85 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 86 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 87 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 89 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 90 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 91 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 92 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 94 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 95 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 96 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 97 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 99 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 100 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 101 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 102 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 104 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 105 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 106 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 107 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 109 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 110 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 111 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 112 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 114 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 115 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 116 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 117 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 119 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 120 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 121 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 122 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 124 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 125 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 126 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 127 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 129 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 130 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 131 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 132 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 134 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 135 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 136 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 137 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138 DENMARK PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 139 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 140 DENMARK STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 141 DENMARK ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 142 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 144 DENMARK DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 145 DENMARK PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 146 DENMARK PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 147 DENMARK PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148 NORWAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 149 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 150 NORWAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151 NORWAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 152 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 154 NORWAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 155 NORWAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 156 NORWAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 157 NORWAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158 FINLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 159 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 160 FINLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 161 FINLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 164 FINLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 165 FINLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 166 FINLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 167 FINLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168 POLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 169 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 170 POLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 171 POLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 172 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 174 POLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 175 POLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 176 POLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 177 POLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 179 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 180 SWEDEN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 181 SWEDEN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 182 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 184 SWEDEN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185 SWEDEN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 186 SWEDEN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 187 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
List of Figure
FIGURE 1 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 2 EUROPE PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PEMPHIGUS VULGARIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE PEMPHIGUS VULGARIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 TWO SEGMENTS COMPRISE THE EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, (2024)
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARIS IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PEMPHIGUS VULGARIS MARKET FROM 2025 TO 2032
FIGURE 15 DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PEMPHIGUS VULGARIS MARKET IN 2025 AND 2032
FIGURE 16 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:-
FIGURE 17 DROC ANALYSIS
FIGURE 18 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 19 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD MILLION)
FIGURE 20 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 21 EUROPE PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 22 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2024
FIGURE 23 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2025-2032 (USD MILLION)
FIGURE 24 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2025-2032)
FIGURE 25 EUROPE PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 26 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2024
FIGURE 27 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, 2025-2032 (USD MILLION)
FIGURE 28 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 29 EUROPE PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 31 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
FIGURE 32 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 33 EUROPE PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2024)
FIGURE 35 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)